Pilot Phase II Study of the PI3K Inhibitor Copanlisib in Combination With a Ketogenic Diet in the Treatment of Patients With Relapsed or Refractory Follicular Lymphoma or Endometrial Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Copanlisib (Primary)
Indications Adenocarcinoma; Endometrial cancer; Follicular lymphoma; Squamous cell cancer
Focus Therapeutic Use

07 Jun 2023 Status changed from recruiting to active, no longer recruiting.
26 May 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
26 May 2023 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com